Kiniksa Pharmaceuticals International, plc (KNSA) is the 35th largest of 300 Biotechnology companies by market capitalisation, at 6.15 Bn, behind Mirum Pharmaceuticals, Inc. at 6.31 Bn. It trades on a P/E of 76.23, 334% above the peer median of 17.56. The table below compares all 300 on 8 financial metrics.
| # | Ticker | Company | match | industry_code | industry_group | industry_group_code | Market Capitalization | P/E | P/S | Enterprise Value |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | AMGN | Amgen Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 211.28 Bn | 24.17 | 5.55 | 197.29 Bn |
| 2 | GILD | Gilead Sciences, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 181.28 Bn | -62.62 | 5.95 | 178.10 Bn |
| 3 | VRTX | Vertex Pharmaceuticals Inc / Ma | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 132.26 Bn | 30.02 | 10.51 | 124.41 Bn |
| 4 | REGN | Regeneron Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 82.58 Bn | 19.08 | 5.32 | 74.58 Bn |
| 5 | ARGX | Argenx Se | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 61.67 Bn | 35.95 | 11.80 | 56.48 Bn |
| 6 | MRNA | Moderna, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 54.58 Bn | -17.32 | 24.50 | 49.44 Bn |
| 7 | ALNY | Alnylam Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 34.01 Bn | 43.90 | 7.08 | 30.70 Bn |
| 8 | BIIB | Biogen Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 31.26 Bn | 37.46 | 3.12 | 29.98 Bn |
| 9 | ROIV | Roivant Sciences Ltd. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 29.78 Bn | -20.07 | 2,726.59 | 29.78 Bn |
| 10 | INSM | INSMED Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 28.17 Bn | -32.18 | 24.76 | 27.01 Bn |
| 11 | BNTX | BioNTech SE | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 23.84 Bn | -13.99 | 7.71 | 10.19 Bn |
| 12 | ASND | Ascendis Pharma A/S | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 15.92 Bn | 18.36 | 11.23 | 14.98 Bn |
| 13 | MDGL | Madrigal Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 15.82 Bn | -49.59 | 12.32 | 14.98 Bn |
| 14 | BBIO | BridgeBio Pharma, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 14.94 Bn | -21.59 | 20.95 | 14.22 Bn |
| 15 | SMMT | Summit Therapeutics Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 13.58 Bn | — | — | 12.89 Bn |
| 16 | BMRN | Biomarin Pharmaceutical Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 12.62 Bn | 172.97 | 3.71 | 11.75 Bn |
| 17 | HALO | Halozyme Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 12.56 Bn | 30.36 | 7.55 | 12.33 Bn |
| 18 | ARWR | Arrowhead Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 11.95 Bn | -43.93 | 17.86 | 10.35 Bn |
| 19 | AAVXF | Abivax S.A. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 10.92 Bn | -25.97 | — | 10.92 Bn |
| 20 | APGE | Apogee Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 10.18 Bn | -34.62 | — | 9.20 Bn |
| 21 | PRAX | Praxis Precision Medicines, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 10.13 Bn | -26.56 | — | 9.37 Bn |
| 22 | PTGX | Protagonist Therapeutics, Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 9.56 Bn | 86.62 | 33.92 | 9.56 Bn |
| 23 | IONS | Ionis Pharmaceuticals Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 9.33 Bn | -43.96 | 10.67 | 7.28 Bn |
| 24 | PCVX | Vaxcyte, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 8.60 Bn | -8.13 | — | 8.60 Bn |
| 25 | IBRX | ImmunityBio, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 8.38 Bn | -8.45 | 50.57 | 8.03 Bn |
| 26 | IMVT | Immunovant, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 7.97 Bn | -14.81 | — | 7.97 Bn |
| 27 | TGTX | Tg Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 7.76 Bn | 17.56 | 9.70 | 7.07 Bn |
| 28 | GIFLF | Grifols SA | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 7.54 Bn | 29.70 | 0.46 | 9.09 Bn |
| 29 | SYRE | Spyre Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 7.48 Bn | -41.80 | — | 7.48 Bn |
| 30 | SRRK | Scholar Rock Holding Corp | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 7.11 Bn | -17.61 | — | 7.11 Bn |
| 31 | RYTM | Rhythm Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 6.92 Bn | -32.90 | 28.83 | 6.59 Bn |
| 32 | BLRX | BioLineRx Ltd. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 6.34 Bn | -707.43 | 4,551.55 | 6.34 Bn |
| 33 | CGON | CG Oncology, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 6.34 Bn | -28.27 | 1,017.25 | 6.34 Bn |
| 34 | MIRM | Mirum Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 6.31 Bn | -7.33 | 10.20 | 5.87 Bn |
| 35 | KNSA | Kiniksa Pharmaceuticals International, plc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 6.15 Bn | 76.23 | 7.31 | 5.62 Bn |
| 36 | COGT | Cogent Biosciences, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 5.91 Bn | -15.98 | — | 5.91 Bn |
| 37 | XENE | Xenon Pharmaceuticals Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 5.86 Bn | -16.15 | — | 5.86 Bn |
| 38 | DBVT | DBV Technologies S.A. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 5.86 Bn | -33.28 | 1,166.98 | 5.68 Bn |
| 39 | LGND | Ligand Pharmaceuticals Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 5.83 Bn | 29.54 | 20.05 | 4.47 Bn |
| 40 | ORKA | Oruka Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 5.79 Bn | — | — | 4.06 Bn |
| 41 | PTCT | Ptc Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 5.62 Bn | 14.69 | 5.57 | 3.39 Bn |
| 42 | CELC | Celcuity Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 4.97 Bn | -22.72 | — | 4.97 Bn |
| 43 | ERAS | Erasca, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 4.96 Bn | -17.26 | — | 4.96 Bn |
| 44 | DNLI | Denali Therapeutics Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 4.09 Bn | -8.00 | 1,134.59 | 4.09 Bn |
| 45 | DNTH | Dianthus Therapeutics, Inc. /DE/ | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 4.02 Bn | — | — | 3.62 Bn |
| 46 | TLPPF | Telix Pharmaceuticals Ltd | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.89 Bn | -521.64 | 4.64 | 3.59 Bn |
| 47 | RLAY | Relay Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.85 Bn | -13.47 | 371.99 | 3.85 Bn |
| 48 | VKTX | Viking Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.80 Bn | -7.11 | — | 3.80 Bn |
| 49 | AMLX | Amylyx Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.64 Bn | -29.97 | — | 3.64 Bn |
| 50 | RCUS | Arcus Biosciences, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.60 Bn | -7.82 | 30.75 | 2.90 Bn |
| 51 | IDYA | IDEAYA Biosciences, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.55 Bn | -16.15 | 15.18 | 2.73 Bn |
| 52 | TNGX | Tango Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.55 Bn | -34.69 | 65.98 | 2.54 Bn |
| 53 | ABCL | AbCellera Biologics Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.40 Bn | -20.65 | 51.37 | 3.40 Bn |
| 54 | DYN | Dyne Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.22 Bn | -6.23 | — | 3.22 Bn |
| 55 | ARQT | Arcutis Biotherapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.11 Bn | 109.33 | 6.71 | 2.88 Bn |
| 56 | CLDX | Celldex Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.02 Bn | -9.82 | 19,105.29 | 3.02 Bn |
| 57 | IMNM | Immunome Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.98 Bn | -11.03 | 593.06 | 2.46 Bn |
| 58 | MBX | MBX Biosciences, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.94 Bn | -28.18 | — | 2.94 Bn |
| 59 | IRON | Disc Medicine, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.94 Bn | -14.58 | — | 2.94 Bn |
| 60 | NRIX | Nurix Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.91 Bn | -8.54 | 79.25 | 2.47 Bn |
| 61 | ZLAB | Zai Lab Ltd | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.82 Bn | -14.96 | 6.26 | 2.11 Bn |
| 62 | SLS | SELLAS Life Sciences Group, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.68 Bn | -82.58 | — | 2.68 Bn |
| 63 | OCUL | Ocular Therapeutix, Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.53 Bn | -8.36 | 48.62 | 2.53 Bn |
| 64 | VERA | Vera Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.46 Bn | -6.15 | — | 2.46 Bn |
| 65 | VRDN | Viridian Therapeutics, Inc.\DE | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.42 Bn | -6.05 | 34.05 | 2.42 Bn |
| 66 | NKTR | Nektar Therapeutics | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.40 Bn | -20.23 | 44.04 | 1.72 Bn |
| 67 | BCRX | Biocryst Pharmaceuticals Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.33 Bn | -6.06 | 4.36 | 1.98 Bn |
| 68 | BHVN | Biohaven Ltd. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.31 Bn | -3.94 | — | 2.05 Bn |
| 69 | XTLB | Xtl Biopharmaceuticals Ltd | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.29 Bn | -2,975.41 | — | 2.29 Bn |
| 70 | URGN | UroGen Pharma Ltd. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.27 Bn | -36.44 | 12.02 | 2.16 Bn |
| 71 | PHVS | Pharvaris N.V. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.23 Bn | -11.24 | — | 1.86 Bn |
| 72 | ADMA | Adma Biologics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.15 Bn | 12.93 | 4.20 | 2.02 Bn |
| 73 | GMAB | Genmab A/S | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.15 Bn | 0.17 | 0.34 | 0.65 Bn |
| 74 | KOD | Kodiak Sciences Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.13 Bn | -8.82 | — | 2.13 Bn |
| 75 | AGIO | Agios Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.10 Bn | -5.09 | 21.32 | 2.10 Bn |
| 76 | RAPP | Rapport Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.07 Bn | -15.11 | 103.62 | 2.07 Bn |
| 77 | CMPS | COMPASS Pathways plc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.05 Bn | -5.21 | — | 2.05 Bn |
| 78 | ZBIO | Zenas BioPharma, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.03 Bn | -4.89 | 2,031.27 | 2.03 Bn |
| 79 | ZYME | Zymeworks Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.00 Bn | -13.31 | 53.77 | 1.73 Bn |
| 80 | STOK | Stoke Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.96 Bn | -9.43 | 71.05 | 1.67 Bn |
| 81 | XNCR | Xencor Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.89 Bn | -11.60 | 18.05 | 1.52 Bn |
| 82 | INBX | Inhibrx Biosciences, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.81 Bn | -13.58 | 1,393.46 | 1.81 Bn |
| 83 | VIR | Vir Biotechnology, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.81 Bn | -7.20 | 5.97 | 1.81 Bn |
| 84 | IMCR | Immunocore Holdings plc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.77 Bn | -97.95 | 4.12 | 0.89 Bn |
| 85 | SNDX | Syndax Pharmaceuticals Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.77 Bn | -9.74 | 7.00 | 1.22 Bn |
| 86 | RXRX | Recursion Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.73 Bn | -3.34 | 31.55 | 1.18 Bn |
| 87 | GLPGF | Lakefront Biotherapeutics NV | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.73 Bn | 0.00 | 1.50 | 1.73 Bn |
| 88 | SEPN | Septerna, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.72 Bn | -123.02 | 17.37 | 1.72 Bn |
| 89 | GHRS | GH Research PLC | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.68 Bn | -27.02 | — | 1.32 Bn |
| 90 | DMRA | Damora Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.65 Bn | -6.27 | — | 1.11 Bn |
| 91 | NVAX | Novavax Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.63 Bn | -6.56 | 3.93 | 0.91 Bn |
| 92 | SCNI | Scinai Immunotherapeutics Ltd. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.62 Bn | -192.89 | 938.23 | 1.61 Bn |
| 93 | BCAX | Bicara Therapeutics Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.60 Bn | -8.63 | — | 1.60 Bn |
| 94 | ANAB | Anaptysbio, Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.60 Bn | -66.89 | 8.02 | 1.31 Bn |
| 95 | ATAI | AtaiBeckley Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.59 Bn | -10.36 | 525.18 | 1.59 Bn |
| 96 | FBRX | Forte Biosciences, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.58 Bn | -20.71 | — | 1.23 Bn |
| 97 | AAPG | Ascentage Pharma Group International | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.54 Bn | -9.11 | 20.12 | 1.26 Bn |
| 98 | RARE | Ultragenyx Pharmaceutical Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.51 Bn | -3.27 | 2.11 | 1.22 Bn |
| 99 | GLUE | Monte Rosa Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.46 Bn | -9.51 | 50.96 | 0.83 Bn |
| 100 | ANRO | Alto Neuroscience, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.46 Bn | -17.45 | — | 1.46 Bn |
| 101 | TYRA | Tyra Biosciences, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.46 Bn | -9.81 | — | 1.46 Bn |
| 102 | MAZE | Maze Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.44 Bn | -13.62 | 72.23 | 1.44 Bn |
| 103 | AVBP | ArriVent BioPharma, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.41 Bn | -8.60 | — | 1.41 Bn |
| 104 | REPL | Replimune Group, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.41 Bn | -4.74 | — | 1.41 Bn |
| 105 | OMER | Omeros Corp | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.40 Bn | 82.07 | 36.46 | 1.40 Bn |
| 106 | ABSI | Absci Corp | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.39 Bn | -11.45 | 888.24 | 1.19 Bn |
| 107 | SVRA | Savara Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.37 Bn | -9.85 | — | 1.37 Bn |
| 108 | ORIC | Oric Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.36 Bn | -8.66 | — | 1.36 Bn |
| 109 | CGEM | Cullinan Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.33 Bn | -6.49 | — | 1.33 Bn |
| 110 | VOR | Vor Biopharma Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.28 Bn | -1.39 | — | 1.28 Bn |
| 111 | ALMS | Alumis Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.27 Bn | -5.23 | 152.28 | 0.77 Bn |
| 112 | MNKD | Mannkind Corp | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.24 Bn | -28.41 | 3.15 | 1.13 Bn |
| 113 | JANX | Janux Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.22 Bn | -11.88 | 50.80 | 1.22 Bn |
| 114 | CRVS | Corvus Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.20 Bn | -25.05 | — | 0.98 Bn |
| 115 | JBIO | Jade Biosciences, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.17 Bn | -7.65 | — | 1.17 Bn |
| 116 | CLYM | Climb Bio, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.15 Bn | -19.95 | — | 1.15 Bn |
| 117 | MLTX | MoonLake Immunotherapeutics | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.02 Bn | -3.85 | — | 0.48 Bn |
| 118 | ABUS | Arbutus Biopharma Corp | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.01 Bn | 6.65 | 5.58 | 0.92 Bn |
| 119 | OKYO | OKYO Pharma Ltd | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.00 Bn | -118.02 | — | 1.00 Bn |
| 120 | WVE | Wave Life Sciences, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.97 Bn | -4.81 | 14.90 | 0.61 Bn |
| 121 | MNPR | Monopar Therapeutics | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.97 Bn | -69.87 | — | 0.92 Bn |
| 122 | GERN | Geron Corp | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.95 Bn | -14.19 | 3.92 | 0.65 Bn |
| 123 | ARDX | Ardelyx, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.95 Bn | -17.07 | 2.11 | 0.67 Bn |
| 124 | ANNX | Annexon, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.89 Bn | -4.37 | — | 0.89 Bn |
| 125 | TBPH | Theravance Biopharma, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.88 Bn | 20.83 | 8.45 | 0.49 Bn |
| 126 | RIGL | Rigel Pharmaceuticals Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.87 Bn | 2.72 | 3.16 | 0.78 Bn |
| 127 | STTK | Shattuck Labs, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.81 Bn | -15.09 | 814.37 | 0.81 Bn |
| 128 | AVTX | Avalo Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.80 Bn | -8.01 | — | 0.80 Bn |
| 129 | ACRS | Aclaris Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.79 Bn | -9.89 | 95.78 | 0.79 Bn |
| 130 | PHAR | Pharming Group N.V. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.78 Bn | -125.18 | 2.34 | 0.62 Bn |
| 131 | CTMX | CytomX Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.77 Bn | -10.18 | 42.17 | 0.44 Bn |
| 132 | ZURA | Zura Bio Ltd | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.72 Bn | -6.18 | — | 0.72 Bn |
| 133 | AURA | Aura Biosciences, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.69 Bn | -6.29 | — | 0.62 Bn |
| 134 | IRWD | Ironwood Pharmaceuticals Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.67 Bn | 3.03 | 1.72 | 0.59 Bn |
| 135 | SLN | Silence Therapeutics plc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.64 Bn | -16.42 | 1,037.67 | 0.57 Bn |
| 136 | ASMB | Assembly Biosciences, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.62 Bn | 501.80 | 8.34 | 0.30 Bn |
| 137 | CBIO | Crescent Biopharma, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.62 Bn | -3.78 | 592.72 | 0.44 Bn |
| 138 | ALT | Altimmune, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.61 Bn | -8.29 | — | 0.61 Bn |
| 139 | OCS | Oculis Holding AG | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.60 Bn | -344,077.60 | — | 0.60 Bn |
| 140 | CTNM | Contineum Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.58 Bn | -9.55 | — | 0.58 Bn |
| 141 | VALN | Valneva SE | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.57 Bn | -9.85 | 3.45 | 0.43 Bn |
| 142 | TECX | Tectonic Therapeutic, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.57 Bn | -6.65 | — | 0.57 Bn |
| 143 | ARVN | Arvinas, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.57 Bn | 61.35 | 1.80 | 0.00 Bn |
| 144 | SGMT | Sagimet Biosciences Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.57 Bn | -11.79 | — | 0.57 Bn |
| 145 | BBOT | BridgeBio Oncology Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.55 Bn | -2.76 | — | 0.32 Bn |
| 146 | IMUX | Immunic, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.51 Bn | -4.45 | — | 0.51 Bn |
| 147 | OABI | OmniAb, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.51 Bn | -11.56 | 13.31 | 0.46 Bn |
| 148 | PRLD | Prelude Therapeutics Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.50 Bn | -7.41 | 22.27 | 0.22 Bn |
| 149 | PRTA | Prothena Corp Public Ltd Co | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.48 Bn | -11.03 | 8.88 | 0.20 Bn |
| 150 | KMDA | Kamada Ltd | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.47 Bn | 15.21 | 2.47 | 0.40 Bn |
| 151 | NEUP | Neuphoria Therapeutics Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.47 Bn | -19.85 | — | 0.45 Bn |
| 152 | RLMD | Relmada Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.47 Bn | -7.62 | — | 0.47 Bn |
| 153 | ANL | Adlai Nortye Ltd. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.47 Bn | -10.27 | 78.36 | 0.23 Bn |
| 154 | PBYI | Puma Biotechnology, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.46 Bn | 15.37 | 1.99 | 0.37 Bn |
| 155 | CCCC | C4 Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.45 Bn | -4.46 | 12.89 | 0.20 Bn |
| 156 | DRUG | Bright Minds Biosciences Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.45 Bn | -15.30 | — | 0.45 Bn |
| 157 | AVIR | Atea Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.42 Bn | -3.08 | — | 0.42 Bn |
| 158 | ARCT | Arcturus Therapeutics Holdings Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.42 Bn | -4.43 | 14.35 | 0.23 Bn |
| 159 | RZLT | Rezolute, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.42 Bn | -5.16 | — | 0.42 Bn |
| 160 | BIOA | BioAge Labs, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.41 Bn | -4.41 | 40.01 | 0.41 Bn |
| 161 | CMPX | Compass Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.41 Bn | -5.04 | — | 0.41 Bn |
| 162 | LRMR | Larimar Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.40 Bn | -2.29 | — | 0.25 Bn |
| 163 | EVMN | Evommune, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.39 Bn | -4.10 | 38.79 | 0.19 Bn |
| 164 | ENTA | Enanta Pharmaceuticals Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.38 Bn | -6.06 | 5.86 | 0.19 Bn |
| 165 | EYPT | EyePoint, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.38 Bn | -1.22 | 135.29 | 0.20 Bn |
| 166 | HMDCF | HUTCHMED (China) Ltd | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.38 Bn | — | — | 0.39 Bn |
| 167 | CATX | Perspective Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.36 Bn | -3.01 | — | 0.36 Bn |
| 168 | WHWK | Whitehawk Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.35 Bn | -4.38 | — | 0.35 Bn |
| 169 | FHTX | Foghorn Therapeutics Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.34 Bn | -5.13 | 9.16 | 0.27 Bn |
| 170 | EPRX | Eupraxia Pharmaceuticals Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.32 Bn | -6.45 | — | 0.32 Bn |
| 171 | ELDN | Eledon Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.32 Bn | -3.86 | — | 0.32 Bn |
| 172 | UPB | Upstream Bio, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.32 Bn | -1.97 | 99.87 | 0.32 Bn |
| 173 | STRO | Sutro Biopharma, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.31 Bn | -2.69 | 3.40 | 0.14 Bn |
| 174 | TRDA | Entrada Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.30 Bn | -1.82 | 64.56 | 0.30 Bn |
| 175 | AGEN | Agenus Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.29 Bn | 3.12 | 2.16 | 0.29 Bn |
| 176 | SABS | SAB Biotherapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.28 Bn | -4.12 | — | 0.28 Bn |
| 177 | BCYC | Bicycle Therapeutics Plc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.28 Bn | -1.48 | 4.61 | 0.28 Bn |
| 178 | ACIU | AC Immune SA | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.28 Bn | -5.20 | 12.71 | 0.28 Bn |
| 179 | EQ | Equillium, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.28 Bn | -15.33 | — | 0.28 Bn |
| 180 | FIXX | Q32 Bio Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.27 Bn | 67.73 | — | 0.16 Bn |
| 181 | GALT | Galectin Therapeutics Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.27 Bn | -9.64 | — | 0.27 Bn |
| 182 | MGNX | Macrogenics Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.26 Bn | -16.24 | 1.56 | 0.15 Bn |
| 183 | ALXO | Alx Oncology Holdings Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.26 Bn | -3.20 | — | 0.26 Bn |
| 184 | ALEC | Alector, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.26 Bn | -2.95 | 18.65 | 0.09 Bn |
| 185 | CYDY | CytoDyn Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.26 Bn | -7.64 | — | 0.26 Bn |
| 186 | AVXL | Anavex Life Sciences Corp. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.26 Bn | -18.19 | — | 0.14 Bn |
| 187 | CAMP | Camp4 Therapeutics Corp | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.25 Bn | -5.09 | 60.46 | 0.25 Bn |
| 188 | IVVD | Invivyd, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.25 Bn | -3.00 | 4.50 | 0.09 Bn |
| 189 | ANTX | AN2 Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.25 Bn | -6.99 | — | 0.25 Bn |
| 190 | KRRO | Korro Bio, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.24 Bn | -2.85 | 98.93 | 0.12 Bn |
| 191 | CGEN | Compugen Ltd | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.23 Bn | 6.62 | 3.15 | 0.15 Bn |
| 192 | SRZN | Surrozen, Inc./DE | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.23 Bn | -3.76 | 19.90 | 0.23 Bn |
| 193 | GLSI | Greenwich LifeSciences, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.23 Bn | -10.10 | — | 0.23 Bn |
| 194 | PYXS | Pyxis Oncology, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.22 Bn | -3.39 | 16.16 | 0.19 Bn |
| 195 | NMRA | Neumora Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.22 Bn | -1.36 | — | 0.22 Bn |
| 196 | KROS | Keros Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.22 Bn | -2.46 | 6.77 | -0.04 Bn |
| 197 | PEPG | PepGen Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.22 Bn | -3.07 | — | 0.22 Bn |
| 198 | PLX | Protalix BioTherapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.21 Bn | 10.07 | 2.64 | 0.17 Bn |
| 199 | ABOS | Acumen Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.21 Bn | -2.03 | — | 0.21 Bn |
| 200 | PRQR | ProQR Therapeutics N.V. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.21 Bn | -4.33 | 9.92 | 0.08 Bn |
| 201 | ARMP | Armata Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.21 Bn | -3.33 | — | 0.18 Bn |
| 202 | FTH | Faeth Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.21 Bn | -1.05 | — | 0.21 Bn |
| 203 | CHRS | Coherus Oncology, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.20 Bn | -1.55 | 4.01 | 0.10 Bn |
| 204 | ADCT | ADC Therapeutics SA | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.20 Bn | -1.36 | 2.65 | -0.02 Bn |
| 205 | ADAG | Adagene Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.20 Bn | -13.14 | 32.66 | 0.20 Bn |
| 206 | CUE | Cue Biopharma, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.19 Bn | -1.92 | 8.65 | 0.18 Bn |
| 207 | ORMP | Oramed Pharmaceuticals Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.19 Bn | 1.14 | — | 0.19 Bn |
| 208 | NBP | NovaBridge Biosciences | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.19 Bn | -2.47 | — | 0.19 Bn |
| 209 | IPHA | Innate Pharma SA | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.18 Bn | -1.14 | 60.09 | 0.18 Bn |
| 210 | QNCX | Quince Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.18 Bn | -2.41 | — | 0.18 Bn |
| 211 | MOLN | Molecular Partners Ag | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.18 Bn | -2.51 | 214.11 | 0.18 Bn |
| 212 | XLO | Xilio Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.17 Bn | -5.53 | 2.71 | 0.04 Bn |
| 213 | OKUR | OnKure Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.17 Bn | -2.72 | — | -0.01 Bn |
| 214 | MDWD | MediWound Ltd. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.16 Bn | -5.11 | 13.38 | 0.12 Bn |
| 215 | RANI | Rani Therapeutics Holdings, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.16 Bn | -4.79 | 32.28 | 0.16 Bn |
| 216 | NGEN | Nervgen Pharma Corp. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.16 Bn | -116.03 | — | 0.16 Bn |
| 217 | MIST | Milestone Pharmaceuticals Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.15 Bn | — | — | -0.02 Bn |
| 218 | ENTX | Entera Bio Ltd. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.15 Bn | -10.37 | — | 0.14 Bn |
| 219 | MSLE | Satellos Bioscience Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.15 Bn | -2.91 | — | 0.15 Bn |
| 220 | IFRX | InflaRx N.V. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.14 Bn | 0.00 | 1,813.85 | -0.04 Bn |
| 221 | SPRB | Spruce Biosciences, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.14 Bn | -2.87 | — | 0.14 Bn |
| 222 | UNCY | Unicycive Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.14 Bn | -4.99 | — | 0.14 Bn |
| 223 | IBIO | iBio, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.13 Bn | -4.00 | 1,320.52 | 0.13 Bn |
| 224 | HURA | TuHURA Biosciences, Inc./NV | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.13 Bn | -4.26 | — | 0.13 Bn |
| 225 | CNTB | Connect Biopharma Holdings Ltd | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.13 Bn | -1.88 | 43.97 | 0.13 Bn |
| 226 | NRXP | NRX Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.13 Bn | -6.07 | 37.26 | 0.10 Bn |
| 227 | INDP | Indaptus Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.13 Bn | -8.62 | — | 0.12 Bn |
| 228 | RFL | Rafael Holdings, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.12 Bn | -4.56 | 124.15 | 0.12 Bn |
| 229 | BDTX | Black Diamond Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.12 Bn | -2.51 | — | 0.01 Bn |
| 230 | PMN | ProMIS Neurosciences Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.11 Bn | -2.72 | — | 0.06 Bn |
| 231 | TLSA | Tiziana Life Sciences Ltd | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.11 Bn | -6.55 | — | 0.11 Bn |
| 232 | GNLX | GENELUX Corp | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.11 Bn | -3.29 | — | 0.11 Bn |
| 233 | CRBP | Corbus Pharmaceuticals Holdings, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.11 Bn | — | — | -0.05 Bn |
| 234 | INO | Inovio Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.11 Bn | -1.41 | — | 0.11 Bn |
| 235 | COYA | Coya Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.11 Bn | -4.88 | 13.59 | 0.07 Bn |
| 236 | CTOR | Citius Oncology, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.10 Bn | -2.25 | 60.89 | 0.10 Bn |
| 237 | PLYX | Polaryx Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.10 Bn | -10.11 | — | 0.09 Bn |
| 238 | ONCY | Oncolytics Biotech Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.10 Bn | -3.18 | — | 0.10 Bn |
| 239 | RLYB | Rallybio Corp | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.09 Bn | 2.08 | 146.54 | 0.09 Bn |
| 240 | ALDX | Aldeyra Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.09 Bn | -3.96 | — | 0.09 Bn |
| 241 | KZIA | Kazia Therapeutics Ltd | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.09 Bn | — | — | 0.09 Bn |
| 242 | RVRC | Revium Rx. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.09 Bn | -118.64 | — | 0.09 Bn |
| 243 | OTLK | Outlook Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.09 Bn | -1.42 | — | 0.08 Bn |
| 244 | ACRV | Acrivon Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.09 Bn | -1.16 | — | 0.09 Bn |
| 245 | PYPD | PolyPid Ltd. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.09 Bn | 2.72 | — | 0.08 Bn |
| 246 | FBIO | Fortress Biotech, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.08 Bn | 10.12 | 1.23 | -0.11 Bn |
| 247 | KLRS | Kalaris Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.08 Bn | -1.76 | — | 0.08 Bn |
| 248 | MAIA | MAIA Biotechnology, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.08 Bn | -3.06 | — | 0.05 Bn |
| 249 | ATHE | Alterity Therapeutics Ltd | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.08 Bn | 0.00 | — | 0.08 Bn |
| 250 | GANX | Gain Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.08 Bn | -4.17 | — | 0.08 Bn |
| 251 | TELO | Telomir Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.07 Bn | -1.48 | — | 0.07 Bn |
| 252 | CRDF | Cardiff Oncology, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.07 Bn | -1.74 | 123.31 | 0.07 Bn |
| 253 | SPRO | Spero Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.07 Bn | 11.80 | 1.45 | 0.02 Bn |
| 254 | DWTX | Dogwood Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.07 Bn | -1.87 | — | 0.07 Bn |
| 255 | XBIT | XBiotech Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.07 Bn | -1.62 | — | 0.07 Bn |
| 256 | HRTX | Heron Therapeutics, Inc. /De/ | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.06 Bn | -7.09 | 0.42 | 0.02 Bn |
| 257 | SCYX | Scynexis Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.06 Bn | -3.26 | 3.06 | -0.06 Bn |
| 258 | ALGS | Aligos Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.06 Bn | -0.83 | 15.65 | 0.03 Bn |
| 259 | RNTX | Rein Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.06 Bn | -1.12 | — | 0.06 Bn |
| 260 | IBO | Impact Biomedical Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.05 Bn | -2.87 | 1,540.61 | 0.05 Bn |
| 261 | MCRB | Seres Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.05 Bn | -0.65 | 28.27 | 0.05 Bn |
| 262 | NMAD | Nomad Power Solutions, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.05 Bn | -7.69 | — | 0.05 Bn |
| 263 | TIL | Instil Bio, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.05 Bn | -1.29 | — | 0.05 Bn |
| 264 | IMMP | IMMUTEP Ltd | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.05 Bn | -0.43 | 5.09 | 0.05 Bn |
| 265 | ALP | Alpha Compute Corp | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.05 Bn | -0.02 | 0.19 | 0.05 Bn |
| 266 | BDRX | Biodexa Pharmaceuticals Plc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.05 Bn | -6.38 | — | 0.04 Bn |
| 267 | PTN | Palatin Technologies Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.05 Bn | -7.79 | 3.79 | 0.05 Bn |
| 268 | HOWL | Werewolf Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.05 Bn | -1.39 | 2.24 | 0.05 Bn |
| 269 | ATYR | aTYR PHARMA INC | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.05 Bn | -0.71 | 294.15 | -0.01 Bn |
| 270 | IMA | ImageneBio, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.04 Bn | — | — | -0.09 Bn |
| 271 | NXTC | NextCure, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.04 Bn | -1.00 | — | 0.04 Bn |
| 272 | EDSA | Edesa Biotech, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.04 Bn | -4.42 | — | 0.04 Bn |
| 273 | ELTX | Elicio Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.04 Bn | -1.10 | — | 0.02 Bn |
| 274 | SER | Serina Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.04 Bn | -1.43 | 311.32 | 0.02 Bn |
| 275 | ATNM | Actinium Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.04 Bn | 3.50 | 1.13 | 0.04 Bn |
| 276 | LITS | Lite Strategy, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.04 Bn | -0.68 | — | 0.03 Bn |
| 277 | MREO | Mereo BioPharma Group plc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.04 Bn | -1.00 | 77.14 | 0.04 Bn |
| 278 | FLNA | Filana Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.04 Bn | -1.58 | — | 0.04 Bn |
| 279 | APLM | Apollomics Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.04 Bn | -3.72 | 4.79 | 0.03 Bn |
| 280 | CNTX | Context Therapeutics Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.04 Bn | -0.76 | — | 0.04 Bn |
| 281 | BETRF | BetterLife Pharma Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | -21.82 | — | 0.04 Bn |
| 282 | BHST | Bioharvest Sciences Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | -3.12 | 0.94 | 0.02 Bn |
| 283 | KYNB | Kyntra Bio, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | 0.17 | 4.33 | 0.03 Bn |
| 284 | KAPA | Kairos Pharma, LTD. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | -6.19 | 0.38 | 0.03 Bn |
| 285 | BRNS | Barinthus Biotherapeutics plc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | -0.74 | — | 0.03 Bn |
| 286 | TAOX | TAO Synergies Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | -1.40 | 39.95 | 0.03 Bn |
| 287 | ADIL | Adial Pharmaceuticals, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | -0.47 | — | 0.03 Bn |
| 288 | YDESW | YD Bio Ltd | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | — | — | 0.03 Bn |
| 289 | CLRB | Cellectar Biosciences, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | -1.23 | — | 0.03 Bn |
| 290 | IGC | IGC Pharma, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | -12.26 | 93.50 | 0.03 Bn |
| 291 | RAPH | Raphael Pharmaceutical Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | -23.02 | — | 0.03 Bn |
| 292 | ABVC | Abvc Biopharma, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | -3.61 | — | 0.03 Bn |
| 293 | RDPTF | Radiopharm Theranostics Ltd | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.02 Bn | -0.28 | 97.58 | 0.02 Bn |
| 294 | NNVC | Nanoviricides, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.02 Bn | -2.88 | — | 0.02 Bn |
| 295 | VRXA | Veraxa Biotech AG - Post de-SPAC | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.02 Bn | -0.30 | 869.19 | 0.02 Bn |
| 296 | LTRN | Lantern Pharma Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.02 Bn | -1.49 | — | 0.02 Bn |
| 297 | EVAX | Evaxion A/S | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.02 Bn | -2.44 | 2.82 | 0.01 Bn |
| 298 | GRDX | GridAI Technologies Corp. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.02 Bn | -1.12 | 261.63 | 0.02 Bn |
| 299 | JSPR | Jasper Therapeutics, Inc. | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.02 Bn | -0.10 | — | 0.02 Bn |
| 300 | DYAI | Dyadic International Inc | primary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 0.02 Bn | -2.59 | 4.87 | 0.01 Bn |